Daniel Q Huang
Overview
Explore the profile of Daniel Q Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
195
Citations
3818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H, et al.
Nat Rev Dis Primers
. 2025 Mar;
11(1):14.
PMID: 40050362
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the umbrella term that comprises metabolic dysfunction-associated steatotic liver, or isolated hepatic steatosis, through to metabolic dysfunction-associated steatohepatitis, the progressive necroinflammatory disease form...
2.
Giri S, Ingawale S, Khatana G, Gore P, Praharaj D, Wong V, et al.
J Gastroenterol Hepatol
. 2025 Feb;
PMID: 40016821
Introduction: Studies have shown a change in the etiological profile of liver cancer globally. We aimed to analyze the burden and changes in etiology of liver cancer in the Asia-Oceania...
3.
Ong Y, Kaewdech A, Huang D, Wong Y
Clin Mol Hepatol
. 2025 Feb;
PMID: 39993417
No abstract available.
4.
Danpanichkul P, Duangsonk K, Chen V, Saokhieo P, Dejvajara D, Sukphutanan B, et al.
Hepatology
. 2025 Feb;
PMID: 39937958
Backgrounds Aims: Hepatitis B virus (HBV)-related liver disease ranks as the seventh leading cause of mortality. Despite advances in prevention and treatment, global disparities in the burden of primary liver...
5.
Tham E, Tan D, Danpanichkul P, Ng C, Syn N, Koh B, et al.
Liver Int
. 2025 Feb;
45(3):e70001.
PMID: 39927433
Background And Aim: The burden of cirrhosis and other chronic liver diseases has changed in recent years due to shifts in the contributing aetiologies. We estimated the burden of cirrhosis...
6.
Wang Y, Oza N, Leo J, Choudhury A, Huang D
Clin Mol Hepatol
. 2025 Feb;
PMID: 39925000
No abstract available.
7.
Souza M, Al-Sharif L, Antunes V, Huang D, Loomba R
Hepatology
. 2025 Feb;
PMID: 39903735
Background And Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver disease. With the advent of multiple therapeutic targets in late-phase clinical drug development for MASH, there is...
8.
Ali F, Nguyen M, Hernaez R, Huang D, Wilder J, Piscoya A, et al.
Gastroenterology
. 2025 Jan;
168(2):267-284.
PMID: 39863345
Background & Aims: Hepatitis B reactivation (HBVr) can occur due to a variety of immune-modulating exposures, including multiple drug classes and disease states. Antiviral prophylaxis can be effective in mitigating...
9.
Chew N, Mehta A, Goh R, Zhang A, Chen Y, Chong B, et al.
Circulation
. 2024 Dec;
151(1):98-119.
PMID: 39723980
There is a new awareness of the widespread nature of metabolic dysfunction-associated steatotic liver disease (MASLD) and its connection to cardiovascular disease (CVD). This has catalyzed collaboration between cardiologists, hepatologists,...
10.
Zhou X, Yip T, Huang D, Muthiah M, Noureddin M, Zheng M
Clin Mol Hepatol
. 2024 Dec;
PMID: 39722613
No abstract available.